AstraZeneca insists Celgene deal about strategy, not cash

LONDON, April 24 (Reuters) - AstraZeneca is getting a $450 million windfall by letting Celgene develop a prized immunotherapy drug for blood cancers but its chief executive insists the deal is about strategy, not cash.